

*International Workshop ‘Ultrafast Beams and Applications’
2-5 July 2019, Yerevan, Armenia*

**Differences in DNA damage and repair
in human cancer and normal cells
after ultrashort pulsed electron beam irradiation**

Targeting the DNA Damage Response in CML cells

Nelly Babayan¹, Bagrat Grigoryan², Lusine Khondkaryan¹, Gohar Tadevosyan¹, Ruzanna Grigoryan¹, Natalya Sarkisyan¹



¹Institute of Molecular Biology NAS of RA

²”CANDLE” Synchrotron Research Institute


Yerevan, 2019

Research overview: DNA damage response in cancer cells

Every cell experiences up to 10^5 spontaneous or induced DNA lesions per day



Targeting DNA damage response in cancer therapy




Synthetic lethal interactions in DNA repair genes implicated in cancer

Pathway	Protein	Syndrome	Primary cancers
HR	BRCA1		breast, ovarian
	BRCA2	Fanconi's anemia	breast, ovarian
	AD54B		non-Hodgkin lymphoma, colon cancer
NHEJ			
	MRE11	Ataxia-telangiectasia- like disorder	colorectal cancer
	LIG4	LIG4 syndrome	Leukemia
	Artemis	Omenn syndrome	Lymphoma
NER			
	XPA	Xeroderma pigmentosum	Skin cancers
	ERCC1	cerebro-oculo-facio-skeletal syndrome	squamous cell carcinoma, head /neck
Crosslink repair			
	FANCA, B, C, D2, E	Fanconi's anemia	Various
<i>etc.</i>			

Olaparib treatment in BRCA-mut patients

B Patients with BRCA mutation (n=136)




- EMA approval: 16th December 2014
- FDA approval: 19th December 2014

Targeting DDR in cancer radiotherapy

COMBINING RADIOTHERAPY WITH DRUGS

Drugs that stop cancer cells repairing their DNA could help make radiotherapy more effective.

RADIOTHERAPY  +  DRUGS




1 Radiotherapy causes damage to cells' DNA. If cells can't repair the damage they die.



2 Healthy cells have lots of ways to repair DNA.



3 Cancer cells rely on certain repair molecules.



4 Drugs that block these molecules could leave the cancer cells unable to repair the damage, causing them to die.

DDR in cancer and normal cells after UPEB radiation

Radiation Source: AREAL

AREAL:

Laser-driven radiofrequency gun-based linear pulsed electron accelerator

Electron beam:

- UHPDR - 1.6×10^{10} Gy/sec
- pulse duration - 0.04×10^{-12} s
- Electron energy – 3.6 MeV

Application

- Potential alternative acceleration technology for ion radiotherapy
- More precise investigation of damage mechanisms

Radiobiological Endpoints

DNA damage and repair



Comparison of DNA damage response (DDR) in cancer and normal cells

Identification of target DNA repair genes/proteins for synthetic lethality therapy

Endpoint:

The level of **DNA damage** in cancer/normal cells

Method: Comet assay




Level of DNA damage in human normal (PBMCs, blood normal cells, female) and cancer (K562, blood cancer cells, female) cells after irradiation (0 h) at the non-lethal, sub-lethal and lethal doses

OTM - Olive Tail moment is defined as the product of the tail length and the fraction of total DNA in the tail




DNA repair in cancer/normal cells

Method: Comet assay



The level of DNA-damage in PBMC (normal) and K562 cell line (cancer) cells **after 3 hours of irradiation**


OTM - Olive Tail moment is defined as the product of the tail length and the fraction of total DNA in the tail



Comparison of the induced primary DNA-damage level and repair kinetics in PBMCs (a) and K562 (b) cells. * $p < 0.05$ in comparison to corresponding control


Phosphorylation of Histone H2AX at DNA Double-Strand Breaks

A Intact DNA




DNA double strand breaks (DSB) are considered the most lethal form of DNA damage

B DSB generation




Repair/signaling factors


C Histone modifications and factor recruitment




γ H2AX is a key regulator of the DNA damage response

D Chromatin remodeling





The representative dot-plot (a1, b1) and histogram (a2, b2) of the level of γ -H2AX in PBMCs (a) and K562 cells (b) after sub-lethal (4 Gy) dose of irradiation



The kinetics of γ -H2AX foci formation in cancer (a) and normal (b) cells after lethal (8 Gy) and sub-lethal (4 Gy) doses of irradiation. * - $p < 0.05$ in comparison with non-irradiated cells

Ionizing radiation induced-DNA SSBs/DSBs repair pathways

Non-Homologous End Joining

NHEJ



FAST

Error-prone

Core protein: DNA-PK

Homologous Recombination Repair

HRR



Slow

Free of errors

Core protein: MRE11

Base Excision Repair

BER




FAST


Free of errors

Core protein: APEX1

DNA SSBs/DSBs repair pathway activation accompanied with cell cycle arrest




G1 - Growth
 S - DNA synthesis
 G2 - Growth and preparation for mitosis
 M - Mitosis (cell division)



No HR HR in repair of one-ended DSBs HR in repair of two-ended DSBs

NHEJ in repair of two-ended DSBs





The activation of repair pathways in cancer/normal cells at the non-lethal level of DNA damages

Method: ELISA



Normal cells

Cancer cells



HRR >> **BER** >> **NHEJ**

NHEJ >> **HRR** >> **BER**





Endpoint:

The activation of repair pathways in cancer/normal cells at the sub-lethal level of DNA damages

Method: ELISA





Normal cells

Cancer cells



BER >> NHEJ >> HRR

NHEJ = HRR >> BER





Endpoint:

The activation of repair pathways in cancer/normal cells at the **lethal** level of DNA damages

Method: ELISA



Normal cells

Cancer cells



NHEJ >> **HRR** >> **BER**

BER >> **NHEJ** = **HRR**



Conclusions/Recommendations

To increase the sensitivity of cancer cells (CML) vs. normal cells

Target for synthetic lethality



Inhibition of DNA-PK
(NHEJ pathway)

Non-lethal dose of irradiation

Normal cells

HRR >> BER >> NHEJ



Cancer cells

NHEJ >> HRR >> BER

Effective DNA repair

Non-effective DNA repair

Decrease the time of dose delivery or fractionation of sub-lethal dose



Acknowledgements



Dr., Prof. V. Tsakanov and Dr. B. Grigoryan – “CANDLE” Synchrotron Research Institute

Dr., Prof. A. Osipov - A.I. Burnazyan Federal Medical and Biophysical Center, Moscow, RF

Dr. Prof. R. Aroutiounian – Yerevan State University

Thanks for Your Attention !!!